The global market for oncology biosimilars is estimated at USD 8 billion in 2025 and is projected to grow from USD 9.48 billion in 2026 to USD 36.90 billion in 2034, exhibiting a CAGR of 18.5% during the forecast period (2025–2034). Oncology Biosimilar Market Size, Share & Trends Analysis Report By Product Type (Monoclonal Antibodies (mAbs), Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF), Immunomodulators), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, Blood Cancer / Hematological Cancers, Other), By Route of Administration (Intravenous (IV), Subcutaneous (SC), Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034
Report Code: SRHI40DR
Last Updated : Sep, 2025
Pages : 110
Author : Debashree Bora
Format : PDF, Excel
Access Market Insights: Download Your Sample Report Now!
Gain an overview of the report's scope and coverage.
Access quantitative and qualitative data that forms part of the final report.
Understand how market segmentations and regional data are presented for both the current and forecast periods.
Explore a comprehensive market definition and the methodology used for market size evaluation.
Discover market share insights about top companies, their industry performance, and strategies.
The sample is available in two formats
We are featured on :
Address:
Office 515 A, Amanora Chambers,
Amanora Park Town, Hadapsar,
Pune 411028, Maharashtra, India.
The sample is available in two formats
